Cargando…
Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy
INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in Italy, accounting for 22% of total deaths. Lowering low-density lipoprotein cholesterol (LDL-C) levels reduces the risk of cardiovascular (CV) events; thus, lipid-lowering therapy (LLT) is the first-lin...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799575/ https://www.ncbi.nlm.nih.gov/pubmed/34718949 http://dx.doi.org/10.1007/s12325-021-01960-y |
_version_ | 1784642091479990272 |
---|---|
author | Sciattella, Paolo Maggioni, Aldo P. Arcangeli, Emanuela Sidelnikov, Eduard Kahangire, Doreen A. Mennini, Francesco S. |
author_facet | Sciattella, Paolo Maggioni, Aldo P. Arcangeli, Emanuela Sidelnikov, Eduard Kahangire, Doreen A. Mennini, Francesco S. |
author_sort | Sciattella, Paolo |
collection | PubMed |
description | INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in Italy, accounting for 22% of total deaths. Lowering low-density lipoprotein cholesterol (LDL-C) levels reduces the risk of cardiovascular (CV) events; thus, lipid-lowering therapy (LLT) is the first-line treatment for patients with ASCVD and hypercholesterolaemia. However, many patients with ASCVD fail to reach LDL-C treatment thresholds, leaving them at greater risk of CV events. Inpatient care accounts for 51% of total expenditure on cardiovascular disease in the European Union, but healthcare resource utilization (HCRU) data for ASCVD in Italy is limited. METHODS: The study analysed healthcare claims data for 17,881 patients with acute coronary syndrome, ischemic stroke or peripheral artery disease from the Umbria 2 and Marche regions of Italy. LLT treatment patterns and CV event rates were collected and HCRU estimated in the year before and after the index event. RESULTS: High-intensity LLTs were prescribed to 44.3% of patients and 49.6% received moderate-/low-intensity LLTs during the 6 months after the index event. The first year CV event rate was 18.0/100 patient-years for patients receiving high-intensity LLTs and 17.2/100 patient-years for those on moderate-/low-intensity LLTs. Higher costs were associated with patients untreated with LLT 6 months post-index event (€8323) than patients prescribed high-intensity (€6278) or moderate-/low-intensity LLTs (€6270). Hospitalization accounted for most of the total costs. CONCLUSIONS: This study found that CV events in secondary prevention Italian patients are associated with substantial HCRU and costs. More intensive LDL-C lowering can prevent CV events, easing the financial burden on the healthcare system. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01960-y. |
format | Online Article Text |
id | pubmed-8799575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-87995752022-02-02 Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy Sciattella, Paolo Maggioni, Aldo P. Arcangeli, Emanuela Sidelnikov, Eduard Kahangire, Doreen A. Mennini, Francesco S. Adv Ther Original Research INTRODUCTION: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in Italy, accounting for 22% of total deaths. Lowering low-density lipoprotein cholesterol (LDL-C) levels reduces the risk of cardiovascular (CV) events; thus, lipid-lowering therapy (LLT) is the first-line treatment for patients with ASCVD and hypercholesterolaemia. However, many patients with ASCVD fail to reach LDL-C treatment thresholds, leaving them at greater risk of CV events. Inpatient care accounts for 51% of total expenditure on cardiovascular disease in the European Union, but healthcare resource utilization (HCRU) data for ASCVD in Italy is limited. METHODS: The study analysed healthcare claims data for 17,881 patients with acute coronary syndrome, ischemic stroke or peripheral artery disease from the Umbria 2 and Marche regions of Italy. LLT treatment patterns and CV event rates were collected and HCRU estimated in the year before and after the index event. RESULTS: High-intensity LLTs were prescribed to 44.3% of patients and 49.6% received moderate-/low-intensity LLTs during the 6 months after the index event. The first year CV event rate was 18.0/100 patient-years for patients receiving high-intensity LLTs and 17.2/100 patient-years for those on moderate-/low-intensity LLTs. Higher costs were associated with patients untreated with LLT 6 months post-index event (€8323) than patients prescribed high-intensity (€6278) or moderate-/low-intensity LLTs (€6270). Hospitalization accounted for most of the total costs. CONCLUSIONS: This study found that CV events in secondary prevention Italian patients are associated with substantial HCRU and costs. More intensive LDL-C lowering can prevent CV events, easing the financial burden on the healthcare system. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-021-01960-y. Springer Healthcare 2021-10-31 2022 /pmc/articles/PMC8799575/ /pubmed/34718949 http://dx.doi.org/10.1007/s12325-021-01960-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Sciattella, Paolo Maggioni, Aldo P. Arcangeli, Emanuela Sidelnikov, Eduard Kahangire, Doreen A. Mennini, Francesco S. Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy |
title | Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy |
title_full | Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy |
title_fullStr | Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy |
title_full_unstemmed | Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy |
title_short | Healthcare Resource Utilization, Cardiovascular Event Rate and Use of Lipid-Lowering Therapies in Secondary Prevention of ASCVD in Hospitalized Patients in Italy |
title_sort | healthcare resource utilization, cardiovascular event rate and use of lipid-lowering therapies in secondary prevention of ascvd in hospitalized patients in italy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799575/ https://www.ncbi.nlm.nih.gov/pubmed/34718949 http://dx.doi.org/10.1007/s12325-021-01960-y |
work_keys_str_mv | AT sciattellapaolo healthcareresourceutilizationcardiovasculareventrateanduseoflipidloweringtherapiesinsecondarypreventionofascvdinhospitalizedpatientsinitaly AT maggionialdop healthcareresourceutilizationcardiovasculareventrateanduseoflipidloweringtherapiesinsecondarypreventionofascvdinhospitalizedpatientsinitaly AT arcangeliemanuela healthcareresourceutilizationcardiovasculareventrateanduseoflipidloweringtherapiesinsecondarypreventionofascvdinhospitalizedpatientsinitaly AT sidelnikoveduard healthcareresourceutilizationcardiovasculareventrateanduseoflipidloweringtherapiesinsecondarypreventionofascvdinhospitalizedpatientsinitaly AT kahangiredoreena healthcareresourceutilizationcardiovasculareventrateanduseoflipidloweringtherapiesinsecondarypreventionofascvdinhospitalizedpatientsinitaly AT menninifrancescos healthcareresourceutilizationcardiovasculareventrateanduseoflipidloweringtherapiesinsecondarypreventionofascvdinhospitalizedpatientsinitaly |